Recently Nair et al. [110] found that in mice model treatment with growth hormone releasing hormone (GHRH) agonist JI-34 can weaken IH-induced neurocognitive deficits, decrease oxidative stress levels, and increase HIF-1α DNA binding and upregulation of IGF-1 and erythropoietin expression, while GHRH antagonist (MIA-602) did not affect any cognitive disorders in OSA mice. This evidence concerns the gene EPO and isolated hemihyperplasia.